<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787497</url>
  </required_header>
  <id_info>
    <org_study_id>NEEVOO.MS</org_study_id>
    <nct_id>NCT04787497</nct_id>
  </id_info>
  <brief_title>The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis</brief_title>
  <official_title>The Neuropsychological Effects of Extra-Virgin Olive Oil in People With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cyprus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Olive Center for Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ellis-Farm, Eliama Daily Value</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cyprus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to examine the effect of a complementary treatment with&#xD;
      High Phenolic Extra Virgin Olive Oil (HPEVOO) on the cognitive and mental health of people&#xD;
      with Multiple Sclerosis (MS), while receiving their standard medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symbol Digits Modalities Test (SDMT)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the SDMT score (0-100 range), over three time points. Higher score indicates better processing speed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>California Verbal Learning Test-Second Edition (CVLT-II)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the CVLT-II score (0-80 range), over three time points. Higher score indicates better auditory-verbal learning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Visuospatial Memory Test-Revised (BVMT-R)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the BVMT-R score (0-36 range), over three time points. Higher score indicates better visuospatial memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wisconsin Card Sorting Test (WCST)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the WCST score over three time points. WCST examines attention, working memory and intellectual flexibility (0-64 score range). Higher scores represent worse performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test (TMT)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the TMT scores over three time points. TMT examines attention, intellectual flexibility and inhibition. Longer time to completion indicates worse performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Vocabulary and Block Design from the Wechsler Adult Intelligence Scale (WAIS)</measure>
    <time_frame>baseline</time_frame>
    <description>It will provide an estimated intelligence quotient (IQ) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Digit Span Test (DST) from WAIS</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the DST score over three time points. DST examines working memory, 0-48 score range, higher scores indicate better working memory function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Word List Generation (WLG) Test</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the WLG score over three time points. WLG examines lexical fluency. The higher the number of words generated, the better is the performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Faux Pas Recognition (FPR) Test</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the FPR score over three time points. FPR examines social cognition. Four different vignettes will be used for every assessment (0-20 score range). Higher scores indicate better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the HADS scores over three time points. HADS examines anxiety, depression and psychological distress. Higher scores (0-42 range) indicate greater levels of anxiety and depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Status Questionnaire (SF-36)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in SF-36 scores over three time points. SF-36 consists of eight scales (0-100 score range each) that examine physical and mental health-related quality of life. The lower the score the more disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>baseline, 6-months, 12-months</time_frame>
    <description>Change will be assessed in the MFIS score over three time points. MFIS examines how often fatigue interferes with daily activities. Higher scores (0-84 score range) indicate greater impact of fatigue on a person's activities.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Phenolic Extra Virgin Olive Oil</intervention_name>
    <description>Participants will be randomly assigned in two groups: the Experimental Group (N= 50) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich EVOO alongside their prescribed medical treatment, whereas the Control Group (N = 50) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of MS&#xD;
&#xD;
          -  Must be between 18 to 65 years of age&#xD;
&#xD;
          -  Both males and females are eligible for participation&#xD;
&#xD;
          -  Must have at least five years of education&#xD;
&#xD;
          -  Must be fluent in Greek language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other neurological, psychiatric or chronic condition&#xD;
&#xD;
          -  Enrollment in other trials/drug studies&#xD;
&#xD;
          -  Experiencing side effects from previous treatments&#xD;
&#xD;
          -  Inadequate visual and auditory acuity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Loizou</last_name>
    <phone>0035796651493</phone>
    <email>loizou.g.maria@ucy.ac.cy</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cyprus</investigator_affiliation>
    <investigator_full_name>Maria Loizou</investigator_full_name>
    <investigator_title>Clinical Psychology Doctorate Student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

